News,Views & Analysis Zydus acquires 100 per cent stake in Mumbai-based Biochem
Mylan receives WHO approval for ‘Second-Line-in-a-Box’ HIV/AIDS treatment
Zydus Cadila has acquired 100 per cent stake in Biochem Pharmaceutical Industries Ltd, one of the top 40 pharma companies in India. A privately-held company headquartered in Mumbai, Biochem is a well-integrated pharma player with a presence in the antibiotics, cardiovascular, anti-diabetic and oncological segments. Biochem has reported sales of ` 264.5 crore for
Mylan Inc recently announced that its subsidiary Mylan Laboratories Ltd (formerly Matrix Laboratories Ltd) has received approval for three AntiRetroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization’s (WHO) Prequalification of Medicines Programme. The products include Atazanavir capsule, 300 mg; Ritonavir tablet, 100 mg (heat-stable); and Tenofovir Disoproxil Fumarate and Lamivudine tablet 300 mg/300 mg, or ‘Second-line-in-a-box’; fixed-dose combination Atazanavir Sulfate and Ritonavir tablets, 300 mg/100 mg; fixed-dose combination Abacavir Sulfate, Lamivudine and Zidovudine tablets, 300 mg/150 mg/300 mg. Heather Bresch, President, Mylan, said, “With these three approvals, Mylan will further enhance our portfolio of more convenient, more affordable treatment options for people in the developing world living with HIV/AIDS. In particular, we are proud to deliver on a previous commitment that we made through an announcement with President Bill Clinton on August 6, 2009 , to lower the price of secondline treatments for patients with drug-resistant HIV in developing countries.”
the year 2010-2011. Established in 1959, Biochem has proven strengths in manufacturing and marketing of antibiotics. The top five brands of the company are Ampilox, Biotax, Monotax, Amicin and Zithrocin which together contribute to 40 per cent of the company’s sales. The acquisition strengthens Zydus’ operations in the Indian pharma market. -Titash Roy Choudhury
Bristol Myers Squibb rated as ‘The Best Big Drug Company Of 2011’ by Forbes Bristol Myers Squibb (BMS) was ranked as ‘The Best Big Drug Company Of 2011’ in the latest issue of Forbes. The share price of the leading pharmaceutical company, which is listed in NYSE, increased 32 per cent to $35 over the course of the year. On this occasion, Pheroze Khan, Managing Director, BMS India,
said, “BMS is poised to become a major player in Indian pharma space despite being a new entrant to the country in 2004.” Lamberto Andreotti, CEO, BMS, has built on the strategy put in place by drug-and-medicaldevice industry veteran James Cornelius, who ran the company for four years starting in 2006.
January 2012 I Modern Pharmaceuticals
23